The government’s controversial controls on private-sector medicine prices delivered immediate and sustained savings after they were implemented in 2004, according to research published earlier this week in peer-review journal PLOS ONE.

The study found there was a significant drop in prices of innovator drugs and generic copies of those that were no longer patent protected...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now